Advances in cancer research最新文献_第7页

Management of pediatric brain tumors in low- and middle-income countries. 低收入和中等收入国家儿童脑肿瘤的管理。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-09-09 DOI: 10.1016/bs.acr.2025.08.004

Nisreen Amayiri, Naureen Mushtaq, Mithra Ghalibafian, Eric Bouffet

引用次数: 0

Supramaximal resection in primary brain tumors. 原发性脑肿瘤的上极切除。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-06-18 DOI: 10.1016/bs.acr.2025.05.006

Vardhaan S Ambati, Shawn L Hervey-Jumper

引用次数: 0

Advanced imaging of IDH-mutant gliomas: Precision in diagnosis and management. idh突变胶质瘤的先进影像学：诊断和治疗的准确性。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-06-18 DOI: 10.1016/bs.acr.2025.05.003

Onur Yildirim, Robert J Young

{"title":"Advanced imaging of IDH-mutant gliomas: Precision in diagnosis and management.","authors":"Onur Yildirim, Robert J Young","doi":"10.1016/bs.acr.2025.05.003","DOIUrl":"10.1016/bs.acr.2025.05.003","url":null,"abstract":"Advancements in imaging techniques and analyses have evolved in parallel with advancements in precision oncology and the transformative changes in glioma diagnosis and management. This chapter explores the pivotal roles of modern qualitative and quantitative imaging in characterizing gliomas, particularly low-grade gliomas (LGGs). Key topics include the integration of standard imaging biomarkers (e.g., T2-FLAIR mismatch sign) and advanced imaging modalities (e.g., 2-hydroxyglutarate [2HG] spectroscopy, diffusion and perfusion imaging) into routine clinical practice. These approaches enhance diagnostic accuracy, facilitate treatment planning, and enable longitudinal monitoring of disease progression. Practical challenges, such as the logistical demands to implement tumor segmentation, variability in imaging acquisition and interpretation, and integration of imaging into decision-making discussions between physicians and patients, are also discussed. Additionally, the role of radiomics and artificial intelligence (AI) in refining tumor characterization and predicting treatment response is explored. The inclusion of emerging therapeutic strategies, including IDH inhibitors and AI-driven imaging tools, underscores this chapter's emphasis on precision-driven innovations. By synthesizing current research and clinical practices, this chapter provides a comprehensive framework for leveraging advanced imaging in glioma care. Improved imaging methodologies not only allow for earlier detection of disease progression but also offer insight into treatment response and resistance mechanisms. As imaging continues to evolve, its integration with molecular and computational tools will further refine personalized approaches in glioma management, ultimately contributing to better patient outcomes.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"166 ","pages":"59-80"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144661434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current advances in the management of atypical teratoid rhabdoid tumors (ATRT). 非典型畸胎瘤样横纹肌样肿瘤（ATRT）治疗的最新进展。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-09-03 DOI: 10.1016/bs.acr.2025.08.007

Michael Angelo Huang, Ashley Margol

{"title":"Current advances in the management of atypical teratoid rhabdoid tumors (ATRT).","authors":"Michael Angelo Huang, Ashley Margol","doi":"10.1016/bs.acr.2025.08.007","DOIUrl":"10.1016/bs.acr.2025.08.007","url":null,"abstract":"Atypical teratoid rhabdoid tumors (ATRT) are rare, often lethal embryonal tumors of the central nervous system (CNS) that primarily affect very young children. Intensive multimodal approaches have resulted in improvements in survival albeit with significant associated toxicity. Recent molecular studies have led to the discovery of SMARCB1 inactivation and resultant BAF47/INI1 loss as the near-universal key genetic event that leads to widespread epigenetic dysregulation. Rarely, SMARCA4 encoding BRG1 is impacted. SMARCB1 and SMARCA4 are core subunits of the SWI/SNF chromatin remodeling complex, which is a fundamental epigenetic regulator of gene transcription. Up to a third of patients diagnosed with ATRT have Rhabdoid Tumor Predisposition Syndrome (RTPS) characterized by germline SMARCB1 (or SMARCA4) alterations. Patients with RTPS are at increased risk of developing synchronous or metachronous rhabdoid tumors outside the CNS. At least three molecular subgroups of ATRT (ATRT-TYR, ATRT-SHH, ATRT-MYC) have been identified through large-scale DNA methylation and transcriptomic studies, with each subgroup having distinct transcriptional, epigenomic and clinicopathologic features. In this book chapter, we will summarize key epidemiological and clinical features of ATRT, review current conventional multimodal regimens, summarize key findings from conducted prospective trials and recently concluded (2020 to present) meta-analyses, as well as discuss emerging targeted treatment approaches that exploit potential therapeutic vulnerabilities of this epigenetically influenced tumor.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"167 ","pages":"185-241"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145461262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AEG-1 on cancer drug resistance: From molecular insights to therapeutic challenges. AEG-1对癌症耐药的影响：从分子洞察到治疗挑战。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-07-11 DOI: 10.1016/bs.acr.2025.06.003

Wali Ullah, Hail Kim, Sanghee Han, Minseo Oh, Dong-Chul Kang, Seok-Geun Lee

{"title":"AEG-1 on cancer drug resistance: From molecular insights to therapeutic challenges.","authors":"Wali Ullah, Hail Kim, Sanghee Han, Minseo Oh, Dong-Chul Kang, Seok-Geun Lee","doi":"10.1016/bs.acr.2025.06.003","DOIUrl":"10.1016/bs.acr.2025.06.003","url":null,"abstract":"Astrocyte elevated gene-1 (AEG-1), also known as metadherin (MTDH), has emerged as a multifunctional oncogene implicated in cancer progression, metastasis, immune evasion, and notably, drug resistance across diverse malignancies. AEG-1 exerts its effects by modulating key signaling cascades, including PI3K/Akt, NF-κB, and Wnt/β-catenin, and by regulating genes associated with epithelial-mesenchymal transition, apoptosis suppression, cancer stemness, and multidrug resistance. Its interactions with molecular partners such as SND1, USP10, and nucleolin further amplify its oncogenic potential, especially in immune suppression and therapy resistance. This review provides a comprehensive overview of AEG-1-mediated drug resistance mechanisms across tumor types including breast, liver, lung, glioma, and gynecological cancers. Tumor-specific signaling contexts and immune microenvironmental interactions are examined to highlight how they shape AEG-1 function. Therapeutic challenges in targeting AEG-1-such as its non-enzymatic structure and intracellular localization-are critically discussed. We further explore emerging strategies to inhibit AEG-1, including RNA interference, long noncoding RNA modulation, partner interaction disruption, phytochemical inhibitors, and nanoparticle-based delivery systems. AEG-1 is also evaluated as a prognostic and predictive biomarker with translational relevance in precision oncology. Future studies should prioritize its integration into biomarker-guided clinical trials and the development of tumor-specific AEG-1-targeted therapies. This review underscores AEG-1 as a central mediator of drug resistance and a compelling target for next-generation cancer therapeutics.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"168 ","pages":"99-129"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145535129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AI-driven parametric FDG brain PET and brain tumor segmentation for multi-modal convolution neural network to differentiate tumor progression from treatment effect in GBM. 人工智能驱动的参数化FDG脑PET和多模态卷积神经网络的脑肿瘤分割，用于区分GBM的肿瘤进展和治疗效果。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-08-26 DOI: 10.1016/bs.acr.2025.07.001

Bijoy Kundu, Zoraiz Qureshi, Rugved Chavan, Afrida Rahman

{"title":"AI-driven parametric FDG brain PET and brain tumor segmentation for multi-modal convolution neural network to differentiate tumor progression from treatment effect in GBM.","authors":"Bijoy Kundu, Zoraiz Qureshi, Rugved Chavan, Afrida Rahman","doi":"10.1016/bs.acr.2025.07.001","DOIUrl":"10.1016/bs.acr.2025.07.001","url":null,"abstract":"Glioblastoma (GBM) accounts for 52 % of all malignant primary brain tumors. The main treatment regimens include surgical resection followed by chemoradiotherapy. Despite these, the median survival of patients with GBM is only 15 months. To make things worse the neuroimaging characteristics mimic tumor recurrence. Traditional static Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) is also unreliable. In this review manuscript we describe advanced PET methods to differentiate tumor progression (TP) from treatment related necrosis (TN) in post treated GBM patients. Dynamic FDG PET (dPET), an advance from traditional static FDG PET, may prove advantageous in clinical staging. Quantifying dPET data is however challenging. In this review we showcase new work for an end-to-end novel AI platform for automated blood input computation to quantify dPET data. Next, we review new work on a large AI model for multimodal brain tumor segmentation from post-treated BraTS2024 MRI datasets and finally a multi-modal AI platform including dPET and MRI for classification of TP vs TN.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"168 ","pages":"131-157"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145535076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in minimally invasive surgery for brain metastases. 微创手术治疗脑转移瘤的进展。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-05-08 DOI: 10.1016/bs.acr.2025.04.003

Nicole A Perez, Bryan D Choi, Brian V Nahed

{"title":"Advances in minimally invasive surgery for brain metastases.","authors":"Nicole A Perez, Bryan D Choi, Brian V Nahed","doi":"10.1016/bs.acr.2025.04.003","DOIUrl":"10.1016/bs.acr.2025.04.003","url":null,"abstract":"Brain metastases (BMs) affect approximately 10-30 % of cancer patients, and their prevalence is growing as patients live longer with controlled primary disease. Surgical resection remains a cornerstone of treatment for both solitary and multifocal lesions. Since the advent of intracranial tumor surgery, neurosurgery has trended towards less invasive surgical approaches, facilitated by a proliferation of surgical innovations ranging from intraoperative MRI to tubular retractors. Minimally invasive cranial surgery (MICS) incorporates approaches such as keyhole craniotomies and tubular retraction with the goal of maximizing extent of resection and reducing iatrogenic tissue injury. Supramarginal resection builds upon this approach, expanding the boundaries of the resection cavity to ensure removal of microscopic tumor fragments and decrease recurrence. Because MICS is generally performed through craniotomies< 5 cm in diameter with limited ability to change predefined surgical corridors intraoperatively, meticulous attention must be given to the preoperative workup. Imaging modalities, including CT, MRI, DWI, and DTI, may reveal characteristics of the intra-tumoral environment and are important in defining the anatomical relationship of BMs to surrounding functional tissue and neurovascular structures. Intraoperatively, neuronavigation helps maintain alignment within predefined surgical corridors, and adjunctive modalities such as intraoperative ultrasound and brain mapping help compensate for brain shift. Advancements in visual augmentation tools such as fluorescence, endoscopes, and exoscopes further enable intraoperative delineation of tumor boundaries and allow for expanded utilization of MICS in deep-seated, complex BMs. The ever-growing armamentarium of minimally invasive surgical tools has made neurosurgery an increasingly safe and effective option for patients with BMs.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"165 ","pages":"165-230"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Precision medicine approaches to CNS metastatic disease. 精准医学方法治疗中枢神经系统转移性疾病。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-05-14 DOI: 10.1016/bs.acr.2025.04.005

Toni Cao, Meaghan Roy-O'Reilly, Seema Nagpal

{"title":"Precision medicine approaches to CNS metastatic disease.","authors":"Toni Cao, Meaghan Roy-O'Reilly, Seema Nagpal","doi":"10.1016/bs.acr.2025.04.005","DOIUrl":"10.1016/bs.acr.2025.04.005","url":null,"abstract":"Brain metastases (BrM) and leptomeningeal metastases (LM) are increasingly common neurologic complications of cancer. The era of precision oncology has ushered in a deeper understanding of the molecular alterations that drive oncogenesis, subsequently informing and accelerating the drug development process. New systemic treatments, including oral tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs) as well as antibody-drug conjugates (ADCs), have substantial intracranial efficacy with meaningful clinical benefit for BrM patients. Our understanding of LM continues to evolve with the development of improved detection methods and an increasing number of brain penetrant therapies. Targeted therapeutics continue to transform the existing treatment landscape and add both choice and complexity to the clinician's calculus when managing patients with BrM and/or LM. Multidisciplinary discussion should ultimately guide all treatment decisions and explore both the benefits and toxicities of various therapy options. Systemic targeted therapies should be considered for patients with asymptomatic or minimally symptomatic small BrM and/or LM. Future studies investigating treatment timing and effective combinatorial strategies are urgently needed.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"165 ","pages":"57-114"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stereotactic radiosurgery for brain metastases. 立体定向放射外科治疗脑转移瘤。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-04-24 DOI: 10.1016/bs.acr.2025.04.001

Stylianos Pikis, Maria Protopapa, Georgios Mantziaris, Mahmoud Osama, Jason Sheehan

{"title":"Stereotactic radiosurgery for brain metastases.","authors":"Stylianos Pikis, Maria Protopapa, Georgios Mantziaris, Mahmoud Osama, Jason Sheehan","doi":"10.1016/bs.acr.2025.04.001","DOIUrl":"10.1016/bs.acr.2025.04.001","url":null,"abstract":"Brain metastases are the most common intracranial malignancies in adults, and, depending on primary tumor type, they may affect up to 50 % of cancer patients. Although advances in systemic and local therapies have led to improvements in patient overall survival and progression free survival, there remains substantial opportunities to improve patient outcomes. Stereotactic radiosurgery (SRS) delivers high doses of ionizing radiation with sub-millimeter accuracy to discrete intracranial tumors. It has emerged as the standard of care for patients with limited number of brain metastases, and it serves as a valuable adjuvant after resection. Moreover, SRS is typically seamlessly integrated into systemic therapy treatment regimens. Continued improvement in SRS technology and growing evidence have led to expansion of SRS indications and introduction of new SRS techniques. Frameless SRS technologies have allowed for treatment of larger lesions and even lesions adjacent to critical structures for which single session SRS would not be prudent. Neoadjuvant SRS has recently been proposed as an alternative to adjuvant SRS and appears to help reduce the risk of leptomeningeal dissemination. These novel SRS techniques require further evaluation through prospective clinical trials and registry based studies. In addition, the concurrent combination of systemic therapies with central nervous system (CNS) activity and SRS has yielded promising results with respect to local control and adverse radiation events rates. The concurrent delivery of SRS, precision medicine, and/or immunotherapy requires further refinements to fully optimize patient outcomes. In this review, we detail the current literature on established and forthcoming indications of SRS for brain metastases.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"165 ","pages":"115-143"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The history of LITT for the treatment of active brain metastasis and radiation necrosis. LITT治疗活动性脑转移和放射性坏死的历史。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-05-08 DOI: 10.1016/bs.acr.2025.04.002

Theresa Gammel, Shawn D'Souza, William Broaddus

引用次数: 0